Imugene has secured $11.12 million through a placement to advance its allogeneic CAR-T therapy azer-cel after early clinical data showed complete responses in BTKi-resistant lymphoma patients.
- Placement raises $11.12 million at $0.095 per share
- Strong institutional support including global pharma participant
- Early Phase 1b data shows 2/2 complete responses in BTKi combination cohort
- Funds to support clinical trials, regulatory milestones, and manufacturing
- Further clinical readouts and major conference presentations expected
Placement Secures Funding Into 2027
Imugene Limited (ASX:IMU) has completed a placement raising approximately $11.12 million through the issuance of 117.1 million new shares priced at 9.5 cents each. The capital injection is set to fund the company’s lead asset, azer-cel, an off-the-shelf allogeneic CAR-T therapy targeting blood cancers, through key clinical and regulatory milestones well into calendar year 2027.
The placement attracted robust support from both existing and new institutional investors, including a global commercial-stage biopharmaceutical company subscribing for about 14% of the raise, subject to shareholder approval. This level of backing underscores growing confidence in Imugene’s clinical progress and strategic direction.
Early Clinical Data Boosts Azer-cel’s Potential
Imugene’s recent clinical updates have provided a strong signal for azer-cel’s efficacy, particularly in patients whose disease has progressed following Bruton's tyrosine kinase inhibitor (BTKi) therapy, a market estimated to exceed US$12 billion annually. The company reported complete responses in the first two evaluable patients in the concurrent BTKi combination cohort of its Phase 1b trial: one with Follicular Lymphoma and another with Mantle Cell Lymphoma.
These initial outcomes not only validate the biological rationale for combining BTKi therapy with CAR-T treatment but also represent the first clinical evidence supporting this approach with azer-cel. The early success may help position Imugene favorably in a highly competitive and lucrative segment of immuno-oncology. BTKi combination cohort
Advancing Trials and Business Development
Proceeds from the placement will primarily support the expansion of Cohort 2 (CAR-T naïve indications) and Cohort 3 (BTKi combination) within the ongoing Phase 1b study. Additional funds will be allocated to regulatory engagement, manufacturing scale-up, and general working capital. Imugene anticipates further patient readouts over the next 6 to 12 months, with data slated for presentation at major scientific conferences such as ASH 2026 and ASCO 2027.
The company also highlighted ongoing business development efforts, including potential partnerships and out-licensing opportunities for azer-cel. The momentum from positive clinical signals combined with fresh capital injection may enhance Imugene’s negotiating position in these discussions.
Placement Structure and Shareholder Approval
The placement was conducted in two tranches: Tranche 1 raised $7 million through the company’s existing placement capacity, while Tranche 2, including a $0.12 million component reserved for directors, is subject to shareholder approval expected at an upcoming extraordinary general meeting in August. The shares issued under Tranche 2 and the directors’ placement will settle and allot shortly after approval.
Notably, the placement shares were issued at a 17.7% discount to the 30-day volume weighted average price and a 29.6% discount to the last closing price prior to the announcement, reflecting a typical concession for quick capital raising in the biotech sector.
Bottom Line?
Imugene’s fresh capital and encouraging early data set the stage for critical clinical milestones and potential partnerships over the next year, but shareholder approval for part of the raise remains a key hurdle.
Questions in the middle?
- Will upcoming clinical data sustain the early complete response momentum in BTKi-resistant patients?
- How will the global pharmaceutical investor’s involvement influence Imugene’s partnership prospects?
- Can azer-cel’s allogeneic CAR-T approach carve a significant niche in the crowded blood cancer therapy market?